Axsome Therapeutics Inc.
Axsome Therapeutics Reports Preliminary 2025 Revenue Growth of 65-66%
Summary
Axsome Therapeutics, Inc. announced preliminary net product revenues for the fourth quarter and full year 2025. Total revenues were $196.0 million for Q4 and $638.5 million for the full year, representing growth of 65% and 66% respectively compared to the previous year. Key products contributing to these revenues include AUVELITY, SUNOSI, and SYMBRAVO. The report is based on unaudited information and final results may vary.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement